Home > Press > OVP Announces New Venture Partner
Early-stage venture capital firm OVP Venture Partners (OVP) today announced the addition of Carl Weissman as Venture Partner. Mr. Weissman will focus on investments in digital biology and the convergence of IT, nanotechnology, and biotechnology.
OVP Announces New Venture Partner
KIRKLAND, WA | Posted on February 7th, 2007
Mr. Weissman is currently the President & CEO of Accelerator, a Seattle-based joint investment vehicle for a syndicate of venture capital investors - including OVP - identifying, investing in, and managing emerging biotechnology opportunities. Under Mr. Weissman's direction, Accelerator has generated a number of drug development companies in which the engine for discovery of novel therapeutics is based upon digital biology.
"We are building on the success of our existing partnership to create even greater opportunities in this space," said OVP General Partner and Accelerator board member Chad Waite. "Carl has unique skills and experience in this field and we are excited to broaden and deepen our relationship with him and with Accelerator."
OVP and Accelerator first announced a partnership in November, 2004. The partnership has successfully incubated new ventures combining advanced information technologies with advanced biotechnology research. Since inception, Accelerator has invested $21.8M in six biotechnology start-ups. One of Accelerator's first graduates, Viral Logic Systems Technology (VLST), raised a $55M Series B round co-led by OVP in June, 2006.
Prior to Accelerator, Mr. Weissman was President and CEO of Centagenetix, where he led the February 2003 merger of Centagenetix with Elixir Pharmaceuticals, remaining on the Board of Directors of the combined entity until January, 2005.
Mr. Weissman will continue to serve as President & CEO of Accelerator.
For over 24 years, OVP Venture Partners has led the drive into new, high-growth technology markets in the Pacific Northwest. OVPís strategy of focusing on early-stage investments in defined spaces has yielded proven results; the firmís record of 51 liquidity events Ė including 22 IPOs Ė leads the region. The OVP team has a passion for working with ground-breaking entrepreneurs and high-caliber investors, and is known for its performance track record and personal integrity. OVP has over $700 million in capital under management and is currently investing its seventh fund.
OVP has offices in Seattle and Portland and concentrates its efforts on opportunities at the intersection of technologyís next big waves and foundational strengths native to the region. The firmís recent activity has included deals in communications, software, security, semiconductor, digital biology, and nanotechnology.
The OVP team includes investing partners Chad Waite, Lucinda Stewart, Rick LeFaivre and Carl Weissman in Seattle and Gerry Langeler, Dave Chen and John Hull in Portland. Chad Waite serves on the Board of the National Venture Capital Association (NVCA).
More information on the partnership is available at http://www.ovp.com .
For more information, please click here
OVP Venture Partners
Sara Morris, 206-851-5590
Copyright © Business Wire
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Champions Oncology, Inc. April 17th, 2014
Nanometrics to Announce First Quarter Financial Results on April 29, 2014 April 9th, 2014
Harris & Harris Group Notes Mersana's Collaboration Agreement With Subsidiary of Takeda Pharmaceutical Co. April 8th, 2014
Harris & Harris Group Continues Its Blog Series to Highlight Most Impactful Portfolio Companies With Metabolon, Inc. April 7th, 2014
MRI, on a molecular scale: Researchers develop system that could one day peer into the atomic structure of individual molecules April 20th, 2014
Iranian Researchers Present New Model to Strengthen Superconductivity at Higher Temperatures April 19th, 2014
Iranian Researchers Produce New Anti-Cancer Drug from Turmeric April 19th, 2014
Innovative strategy to facilitate organ repair April 18th, 2014
Virus structure inspires novel understanding of onion-like carbon nanoparticles April 10th, 2014
Peer Reviewed and Approved for Science by the the Washington Academy of Sciences April 3rd, 2014
New JEOL-Nikon MiXcroscopy Correlative Imaging Solution March 27th, 2014
Quantum Dots Take Center Stage at Inaugural Event: QD Vision Co-Founder and CTO Dr. Seth Coe-Sullivan to Chair First Quantum Dots Forum, March 26, 2014, San Diego, CA March 25th, 2014